Company: NCEL
Filing Date: 2025-01-08
Form Type: 425
Source: 0001213900-25-001822
Chunk: 1

Company: NewcelX Ltd.
Filing Date: 2025-01-08
Form: 425
Chunk 1
---
8, 2025 | NLS Pharmaceutics Ltd. 
 By:                    | /s/ Alexander Zwyer |                         |
|:----------------------|:-----------------------|:--------------------|:------------------------|
|                       |                        | Name:               | Alexander Zwyer         |
|                       |                        | Title:              | Chief Executive Officer |

<div align='center'>2</div>

Exhibit 99.1

NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce the Initial Closing of $500,000 of the Previously Announced $1 Million Fundraising by NLS Following its Extraordinary General Meeting at a Share Price of $3.10, Representing 48% Above the Market Share Price as of Jan 6, 2025

ZURICH, SWITZERLAND and NESS ZIONA,
ISRAEL— January 8, 2025 — NLS Pharmaceutics Ltd. (“NLS”) (Nasdaq: NLSP), a Swiss clinical-stage
biopharmaceutical company focused on the discovery and development of innovative therapies for rare and complex central nervous
system disorders, and Kadimastem Ltd. (“Kadimastem”) (TASE: KDST.TA), a clinical-stage cell therapy company developing
and manufacturing “off-the-shelf” allogeneic cell products for the treatment of neurodegenerative diseases and potential
cure of diabetes, announce the successful completion of the initial closing of $500,000 of the previously announced $1 million
financing between NLS and an accredited investor under a securities purchase agreement dated December 4, 2024, with the approval of
certain items in NLS’s extraordinary general meeting on January 7, 2025. As previously detailed in NLS’s Report on Form
6-K submitted to the Securities and Exchange Commission on December 4, 2024, this agreement involved no warrants and was executed at
a share price of $3.10, representing 48% above the NLS market closing share price as of Jan 6, 2025, the last trading day prior to
the date of the NLS’s extraordinary general meeting.

This financing, along with the previously
announced $3.2 million investment in NLS dated October 2024, is an important step in facilitating the previously
announced proposed merger with Kadimastem, which aims to create a combined Nasdaq-traded biotechnology company